Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy

Bibliographic Details
Main Authors: R. Morales Barrera, N. Díaz, C. Suarez, M. Gonzalez, E. Serra, F. Lozano, M. Altabas, C. Fernandez, M. Hernández, S. Gutierrez, M. Semidey, R. Mast, J.M. Rodriguez, S. Roche, C. Serrano, J. Mateo, C. Valverde, I. De Torres, X. Maldonado, J. Morote, J. Carles
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320336569
_version_ 1818382017705803776
author R. Morales Barrera
N. Díaz
C. Suarez
M. Gonzalez
E. Serra
F. Lozano
M. Altabas
C. Fernandez
M. Hernández
S. Gutierrez
M. Semidey
R. Mast
J.M. Rodriguez
S. Roche
C. Serrano
J. Mateo
C. Valverde
I. De Torres
X. Maldonado
J. Morote
J. Carles
author_facet R. Morales Barrera
N. Díaz
C. Suarez
M. Gonzalez
E. Serra
F. Lozano
M. Altabas
C. Fernandez
M. Hernández
S. Gutierrez
M. Semidey
R. Mast
J.M. Rodriguez
S. Roche
C. Serrano
J. Mateo
C. Valverde
I. De Torres
X. Maldonado
J. Morote
J. Carles
author_sort R. Morales Barrera
collection DOAJ
first_indexed 2024-12-14T02:43:47Z
format Article
id doaj.art-d06e0c01645f4fdfb0a7688a62d21a90
institution Directory Open Access Journal
issn 2666-1683
language English
last_indexed 2024-12-14T02:43:47Z
publishDate 2020-07-01
publisher Elsevier
record_format Article
series European Urology Open Science
spelling doaj.art-d06e0c01645f4fdfb0a7688a62d21a902022-12-21T23:19:56ZengElsevierEuropean Urology Open Science2666-16832020-07-0119e1585Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapyR. Morales BarreraN. DíazC. SuarezM. GonzalezE. SerraF. LozanoM. AltabasC. FernandezM. HernándezS. GutierrezM. SemideyR. MastJ.M. RodriguezS. RocheC. SerranoJ. MateoC. ValverdeI. De TorresX. MaldonadoJ. MoroteJ. Carleshttp://www.sciencedirect.com/science/article/pii/S2666168320336569
spellingShingle R. Morales Barrera
N. Díaz
C. Suarez
M. Gonzalez
E. Serra
F. Lozano
M. Altabas
C. Fernandez
M. Hernández
S. Gutierrez
M. Semidey
R. Mast
J.M. Rodriguez
S. Roche
C. Serrano
J. Mateo
C. Valverde
I. De Torres
X. Maldonado
J. Morote
J. Carles
Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
European Urology Open Science
title Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
title_full Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
title_fullStr Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
title_full_unstemmed Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
title_short Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
title_sort impact of fgfr3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum based chemotherapy
url http://www.sciencedirect.com/science/article/pii/S2666168320336569
work_keys_str_mv AT rmoralesbarrera impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT ndiaz impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT csuarez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT mgonzalez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT eserra impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT flozano impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT maltabas impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT cfernandez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT mhernandez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT sgutierrez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT msemidey impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT rmast impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT jmrodriguez impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT sroche impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT cserrano impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT jmateo impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT cvalverde impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT idetorres impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT xmaldonado impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT jmorote impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy
AT jcarles impactoffgfr3genomicaberrationsinpatientswithmetastaticurothelialcarcinomatreatedwithfirstlineplatinumbasedchemotherapy